In an agreement announced today at Chicagoland Speedway, Aspen Dental Management, Inc. (ADMI) has extended its partnership with Danica Patrick and Stewart Haas Racing (SHR), doubling the number of races in which Aspen Dental serves as primary sponsor. The deal means that Patrick will be behind the wheel of the blue-and-white No. 10 Aspen Dental Chevrolet SS for four races annually beginning with the 2016 NASCAR Sprint Cup Series season, with associate sponsorship status for Patrick in all other Sprint Cup races.
“Working with Aspen Dental dentists has been a real pleasure,” Patrick said. “I love partnering with organizations that care about people, and teaming up with an organization that has such an important mission – breaking down barriers and helping patients get the dental care they need – is very rewarding. Aspen Dental dentists raise awareness about the importance of oral health every day, and I look forward to shining a spotlight on the great work they do.”
Aspen Dental practices are one of the largest and fastest-growing networks of independent dental care providers in the United States, with more than 500 locations across 32 states. In the past two years, Patrick has served as an ambassador for Aspen Dental practices across a multitude of channels, from launching Aspen Dental’s Healthy Mouth Movement, a community-giving initiative to deliver free dental care and oral health education to people in need, to appearing in A Taste of the Future, a hidden camera video designed to raise awareness about the long-term consequences of delaying dental care.
To view the multimedia release go to:
http://www.multivu.com/players/English/7629351-aspen-dental-shr-partnership/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
When a serious illness enters a family's life, there are many questions to ask and decisions to make. It is important to answer these questions quickly. The process can seem overwhelming. However, hospice care can be a wonderful resource for information about symptom management and comfort care. Hospice care professionals are available to help assess goals, pain management and care options during the decision-making process.
Are your symptoms minimal or moderate? Are these symptoms just starting to affect your life? If you want to continue treatment but also need comfort and symptom management, palliative care (often called comfort care) maybe an option. Palliative care is patient and family-centered care that optimizes quality of life by anticipating, preventing and treating suffering. Palliative care specialists address the physical, intellectual, emotional, social, and spiritual needs of patients and families, making sure they have access to all the information about the disease progression and the choices ahead. A patient can receive palliative care in conjunction with other treatments or therapies.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer. The study from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project appears in the November 19 edition of the New England Journal of Medicine.
Ultimately, researchers anticipate that systematic monitoring of patients and family members who have germline mutations in cancer predisposition genes will allow the detection of cancers at their earliest and most curable stage, thereby improving the outcomes for these children and family members.
To view the multimedia release go to:
http://www.multivu.com/players/English/7692851-st-jude-hospital-genome-project/
Long before it's time for hospice care, many people with serious illness can benefit from palliative care but don’t realize it. Sometimes referred to as “comfort care,” palliative care is a specialized approach to the treatment of patients with a serious or life-threatening illness. Palliative care has helped Deadra Gladden get her life back through symptom management and support from Samaritan Healthcare & Hospice, Marlton, N.J.
In May of 2014 Deadra, age 28, was in the hospital, feeling hopeless and in excruciating pain due to lupus, a disease she has been battling for over half her young life. Deadra's doctors told her family it was time to call hospice. But after consulting with a nurse from Samaritan Healthcare and Hospice, a palliative care team was brought in instead.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7562351-lung-care-asthma-mobile-app/
